Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
10.78
USD
|
+2.96%
|
|
-0.65%
|
-25.76%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
216.4
|
247.8
|
518.4
|
388.2
|
-
|
-
|
Enterprise Value (EV)
1 |
216.4
|
247.8
|
518.4
|
388.2
|
388.2
|
388.2
|
P/E ratio
|
-4.28
x
|
-3.01
x
|
-4.22
x
|
-2.64
x
|
-2.7
x
|
-2.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
155
x
|
108
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
155
x
|
108
x
|
EV / EBITDA
|
-
|
-2.99
x
|
-4.16
x
|
-2.26
x
|
-2.01
x
|
-1.8
x
|
EV / FCF
|
-5.6
x
|
-3.91
x
|
-
|
-2.83
x
|
-2.56
x
|
-2.06
x
|
FCF Yield
|
-17.8%
|
-25.6%
|
-
|
-35.3%
|
-39.1%
|
-48.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
29,045
|
29,396
|
35,706
|
36,009
|
-
|
-
|
Reference price
2 |
7.450
|
8.430
|
14.52
|
10.78
|
10.78
|
10.78
|
Announcement Date
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
2.5
|
3.606
|
EBITDA
1 |
-
|
-
|
-82.94
|
-124.6
|
-171.7
|
-193.1
|
-215.3
|
EBIT
1 |
-
|
-41.67
|
-83.63
|
-126.1
|
-160.3
|
-180.8
|
-216.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-7,232.16%
|
-5,995.61%
|
Earnings before Tax (EBT)
1 |
-
|
-41.57
|
-81.83
|
-117.3
|
-156.4
|
-176
|
-215.3
|
Net income
1 |
-5.324
|
-41.57
|
-81.83
|
-117.3
|
-157.2
|
-178.8
|
-215.2
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-7,150.86%
|
-5,966.69%
|
EPS
2 |
-0.5000
|
-1.740
|
-2.800
|
-3.440
|
-4.087
|
-3.992
|
-4.054
|
Free Cash Flow
1 |
-
|
-38.61
|
-63.45
|
-
|
-137
|
-151.7
|
-188.3
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,066.67%
|
-5,222.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/12/21
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-17.3
|
-23.31
|
-26.1
|
-29.74
|
-27.27
|
-30.7
|
-36.91
|
-
|
-41.35
|
-42.85
|
-44.31
|
-
|
EBIT
1 |
-12.64
|
-14.74
|
-16.4
|
-17.47
|
-23.48
|
-26.28
|
-30.03
|
-27.66
|
-31.12
|
-37.33
|
-37.33
|
-39.26
|
-40.95
|
-43.61
|
-42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.61
|
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.46
|
-39.9
|
-41.29
|
-42
|
Net income
1 |
-12.61
|
-14.71
|
-16.37
|
-17.26
|
-22.89
|
-25.31
|
-29.05
|
-24.89
|
-28.43
|
-34.88
|
-34.88
|
-38.3
|
-39.93
|
-42.43
|
-42
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4300
|
-0.5100
|
-0.5600
|
-0.5900
|
-0.7800
|
-0.8600
|
-0.9800
|
-0.7000
|
-0.8000
|
-0.9800
|
-0.9800
|
-1.073
|
-1.081
|
-1.110
|
-1.150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/28/22
|
5/16/22
|
8/1/22
|
11/7/22
|
3/28/23
|
5/2/23
|
7/31/23
|
10/30/23
|
3/28/24
|
4/1/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.6
|
-63.4
|
-
|
-137
|
-152
|
-188
|
ROE (net income / shareholders' equity)
|
-
|
-45.2%
|
-57%
|
-
|
-96.2%
|
-92.4%
|
-114%
|
ROA (Net income/ Total Assets)
|
-
|
-33.5%
|
-52%
|
-
|
-79%
|
-83.8%
|
-84.1%
|
Assets
1 |
-
|
124.1
|
157.5
|
-
|
199
|
213.4
|
256
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
3.17
|
1.03
|
-
|
3.67
|
3.85
|
4.23
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
154%
|
117.17%
|
Announcement Date
|
4/12/21
|
2/28/22
|
3/28/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
10.78
USD Average target price
49.38
USD Spread / Average Target +358.02% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.76% | 388M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|